Natixis Advisors LLC Purchases 1,009 Shares of Merit Medical Systems, Inc. (NASDAQ:MMSI)
Most Americans not aware that alcohol ups cancer risk: Survey
Miguel Tomley scores 28 to lead Weber State over Pepperdine 68-53 at Arizona Tip-OffNoneB. Riley Financial Provides Update on Quarterly Filing Process
SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Humacyte, Inc. HUMA . The lawsuit seeks to recover losses on behalf of investors who acquired securities between May 10, 2024 and October 17, 2024. Investors have until January 17, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit. If you incurred significant losses and want to act as the lead plaintiff in the Humacyte class action lawsuit or determine if you are eligible to receive a potential recovery of your losses, please submit your details here: https://www.johnsonfistel.com/investigations/humacyte Contact for More Information: James Baker, (619) 814-4471, jimb@johnsonfistel.com or fjohnson@johnsonfistel.com According to the lawsuit, during the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Humacyte's Durham, North Carolina facility failed to comply with good manufacturing practices, including quality assurance and microbial testing; (2) the Food and Drug Administration's ("FDA") review of the Biologics License Application ("BLA") would be delayed while Humacyte remediated these deficiencies; and (3) as a result, there was a substantial risk to FDA approval of Acellular Tissue Engineered Vessel ("ATEV") for vascular trauma; and (4) as a result of the foregoing, defendants' positive statements about Humacyte's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages. Investor Action Steps: Shareholders who incurred losses during the class period, have until January 17, 2025 , to move the court to become a lead plaintiff in this action. A lead plaintiff will act on behalf of all other class members in directing the class-action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the class-action lawsuit. An investor's ability to share any potential future recovery of the class action lawsuit is not dependent upon serving as lead plaintiff. About Johnson Fistel, LLP | Top Law Firm, Securities Fraud, Investors Rights: Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. We also extend our services to foreign investors who have purchased on US exchanges. Stay updated with news on stock drops and learn how Johnson Fistel, LLP can help you recover your losses. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com . Attorney advertising. Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Johnson Fistel, LLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content. Contact: Johnson Fistel, LLP 501 W. Broadway, Suite 800, San Diego, CA 92101 James Baker, Investor Relations or Frank J. Johnson, Esq., (619) 814-4471 jimb@johnsonfistel.com or fjohnson@johnsonfistel.com © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
NoneLions rush for 3 scores and use stingy defense to beat Colts 24-6 for 9th straight winJHVEPhoto Ulta Beauty ( NASDAQ: ULTA ) has seen its shares slide 12.7% in the past month to $343.26 as news came out of Berkshire Hathaway ( BRK.B ) ( BRK.A ) reversed course on its investment decision only quarters earlier Analyst’s Disclosure: I/we have a beneficial long position in the shares of ULTA either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. I am long ULTA with an average cost base of $378.03.Disclaimer: While the information and data presented in my articles are obtained from company documents and/or sources believed to be reliable, they have not been independently verified. The material is intended only as general information for your convenience, and should not in any way be construed as investment advice. I advise readers to conduct their own independent research to build their own independent opinions and/or consult a qualified investment advisor before making any investment decisions. I explicitly disclaim any liability that may arise from investment decisions you make based on my articles. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Colorado's 2-way star Travis Hunter eyes Big 12 title and more before 'for sure' entering NFL draft
Tapestry Inc. stock rises Tuesday, still underperforms market
RSU solicits donations for proposed Center for Science and Technology
Unlock Free PSN Codes! Discover the Future of Gaming Rewards